155. Tumor Necrosis In Vivo Caused by a Novel Combination of Sorafenib and Rapamycin: Targeting the RAS and Motor Pathways ION Hepatocellular Carcinoma
Pippa Newell(Hood Technology (United States)), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Stijn van Laarhoven(Icahn School of Medicine at Mount Sinai), Isabel Fiel(Mount Sinai Hospital), Judit Peix, Augusto Villanueva(NYU Langone Health), Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Steven Yea(Array BioPharma (United States)), Sasan Roayaie(White Plains Hospital), Myron Schwartz(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury
|Journal of Biological Chemistry|2000|2.1k